Safinamide Methanesulfonate
Safinamide methanesulfonate was approved by European Medicine Agency (EMA) on Feb 22, 2015. It was developed by Newron and Zambon, then marketed as Xadago® by Zambon in EU.
Safinamide is a unique molecule with a novel dual mechanism of action based on the enhancement of the dopaminergic function (through potent reversible inhibition of MAO-B and of dopamine uptake) and inhibition of the excessive release of glutamate. It is indicated for the treatment of Parkinson's disease (PD).
Xadago® is available as film-coated tablet for oral use, containing Eq. 50 mg/100 mg of free Safinamide. The recommended dose is 50 mg or 100 mg once daily.
Update Date：2015-09-18
- Drug Name：
- Safinamide Methanesulfonate
- Research Code：
- ZP-034; EMD-1195686
- Trade Name：
- Xadago®
- MOA：
- MAO-B inhibitor; Sodium channel blocker; Glutamate release inhibitor; Dopamine receptor
- Indication：
- Parkinson's disease (PD)
- Status：
- Approved
- Company：
- Newron (Originator) , Zambon
- Sales：
- ATC Code：
Update Date：2015-07-29
| Approval Date | Approval Type | Trade Name | Indication | Dosage Form | Strength | Company | Review Classification |
|---|---|---|---|---|---|---|---|
| 2015-02-24 | First approval | Xadago | Parkinson's disease (PD) | Tablet, Film coated | Eq. 50 mg/100 mg Safinamide | Zambon |
Update Date：2015-10-30
|
Molecular Weight | 398.45 | ||||||||||||
| Formula | C17H19FN2O2 ● CH4O3S | |||||||||||||
| CAS No. |
133865-89-1 (Safinamide); 202825-46-5 (Safinamide Mesylate); |
|||||||||||||
| Chemical Name | Propanamide, 2-[[[4-[(3-fluorophenyl)methoxy]phenyl]methyl]amino]-, (2S)-, methanesulfonate (1:1) | |||||||||||||
| Safinamide （Free Acid/Base）Parameters： | ||||||||||||||
|
||||||||||||||
| *：Calculated by ACD/Labs software V11.02. | ||||||||||||||
Update Date：2015-10-30
Update Date：2016-02-21
